Showing results (911-920 of 1,211) with videos related to

Sort By:
Pageof 122
Journal of the American College of Cardiology|November 3, 2024
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation. Heart Failure|December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trialSanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
Journal of the American College of Cardiology|April 23, 2021
Incidence and Outcomes of Pneumonia in Patients With Heart FailureLi Shen, Pardeep S Jhund, Inder S Anand, et al.
JACC. Heart Failure|September 16, 2022
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionPeder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|August 26, 2023
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trialMaria Pabon, Brian L Claggett, Xiaowen Wang, et al.
JACC. Heart Failure|January 6, 2026
Subgroups and Special Populations in Heart Failure Clinical Trials: Insights From the HFC-ARC Expert Consensus PanelVanessa Blumer, Biykem Bozkurt, Marvin A Konstam, et al.
JACC. Heart Failure|May 10, 2024
Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i TherapyVeraprapas Kittipibul, Muthiah Vaduganathan, Uchechukwu Ikeaba, et al.
JACC. Heart Failure|February 5, 2025
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVERMingming Yang, Toru Kondo, Atefeh Talebi, et al.
JACC. Advances|November 28, 2024
Electronic Nudge Letters to Increase Influenza Vaccination Uptake in Younger and Middle-Aged Individuals With DiabetesMats C Højbjerg Lassen, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
JACC. Heart Failure|September 2, 2025
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF)Maja Cikes, Jasper J Brugts, Brian Claggett, et al.
Pageof 122